Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms INOVATYON
- 10 Jun 2017 Biomarkers information updated
- 10 Sep 2014 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2014 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov.